Highest-materiality recent filing
BeOne Medicines Q2 revenue up 30% to $1.7B; raises FY2026 guidance
Q2 total revenue $1.71B (+30% YoY); BRUKINSA revenue $1.2B (+31% YoY).
BeOne Medicines settles China tax audit; pays ~RMB 446M in Q2 2026
Settled statutory tax audit in China; payment of approx. RMB 446 million (including surcharges and interest) to be recognized in Q2 2026.
BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL
FDA approved BEQALZI for R/R mantle cell lymphoma after ≥2 prior therapies including a BTK inhibitor.
BeOne Q1 2026: revenue $1.5B (+35%), BRUKINSA $1.1B (+38%), diluted EPS $1.96/$3.24
Total global revenue $1.5B for Q1 2026, up 35% from prior year.
BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B
Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)
BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B
Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).
BeOne Medicines secures $1B senior secured financing facilities with HSBC-led syndicate
Facilities include $140M B1 revolver, $560M B2 term loan (USD), and ~$300M A term loan (RMB), totaling $1B.
BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09
Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.
BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025
Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.
BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M
Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.
BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84
Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.
Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.
Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.
USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR
USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.
BeiGene files 2024 STAR annual report; US GAAP revenue $3.81B, gross margin down
Revenue $3.81B in 2024, up 55% YoY from $2.46B; gross margin 85.1% vs 84.5% prior year.
BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B
Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).
BeiGene expects positive operating income for FY 2025 under US GAAP at J.P. Morgan conference
Announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.
BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037
Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.
BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income
Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).
BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M
Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.
BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income
Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).
BeiGene names Aaron Rosenberg CFO effective July 22; Julia Wang resigns
Aaron Rosenberg appointed CFO effective July 22; Julia Wang resigns effective July 19, stays as Senior Advisor through Aug 31.
BeiGene shareholders approve equity plan share increases and director re-elections at AGM
Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.
BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M
Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.
EC approves BeiGene's tislelizumab for three NSCLC indications in EU
EC approved tislelizumab on April 23, 2024 for first-line squamous NSCLC, first-line non-squamous PD-L1≥50%, and second-line after prior platinum therapy.
FDA approves BeiGene's TEVIMBRA for ESCC after prior chemo; available H2 2024
FDA approved TEVIMBRA (tislelizumab) for ESCC after prior chemo; first US indication; available H2 2024.
BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows
Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).
BeiGene Q3 revenue $781M (+102% YoY); net income of $215M vs loss of $558M last year
Global product sales up 70% to $595M; BRUKINSA sales $358M (+130%) led by US launch momentum.
BeiGene's BRUKINSA receives positive NICE recommendation for CLL in UK
NICE final draft guidance recommends BRUKINSA for untreated CLL with 17p deletion or TP53 mutation, or when FCR/BR unsuitable, and for relapsed or refractory CLL.
BeiGene receives EC approval for TEVIMBRA in ESCC; FDA accepts BLA for first-line ESCC
EC approved TEVIMBRA (tislelizumab) as monotherapy for adult patients with unresectable, locally advanced or metastatic ESCC after prior platinum-based chemotherapy.
BeiGene regains full global rights to tislelizumab after terminating Novartis license agreement
On September 17, 2023, BeiGene Switzerland and Novartis mutually terminated the Collaboration and License Agreement for tislelizumab, effective immediately.
Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.
Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.
Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.
Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing Yi, whose terms expired at the Annual Meeting, did not stand for re-election at the Annual Meeting.
appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.
On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).
On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.
Mr. Ball assumes the role of principal accounting officer from Julia Wang, the Company’s Chief Financial Officer, who previously served as the Company’s principal financial officer and principal accounting officer.
On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.
On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).
On June 22, 2022, Timothy Chen resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).
On March 2, 2022, Jane Huang, M.D., Chief Medical Officer, Hematology of BeiGene, Ltd. (the “Company”), provided notice of her resignation from the Company effective April 3, 2022.
Max materiality 0.85 · Median 0.65 · Most common event other_material